Roche Holding AG (SWX:ROP)
Switzerland · Delayed Price · Currency is CHF | Market Cap | 283.45B +35.1% |
| Revenue (ttm) | 62.96B -0.8% |
| Net Income | 12.34B +30.9% |
| EPS | 15.33 +30.6% |
| Shares Out | 796.77M |
| PE Ratio | 23.16 |
| Forward PE | 16.85 |
| Dividend | 9.80 (2.76%) |
| Ex-Dividend Date | Mar 12, 2026 |
| Volume | 1,139,472 |
| Open | 350.00 |
| Previous Close | 349.50 |
| Day's Range | 349.60 - 357.30 |
| 52-Week Range | 243.90 - 374.90 |
| Beta | 0.34 |
| Analysts | Buy |
| Price Target | 361.72 (+1.86%) |
| Earnings Date | Jul 23, 2026 |
About Roche Holding AG
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavir... [Read more]
Financial Performance
In 2025, Roche Holding AG's revenue was 63.36 billion, an increase of 1.54% compared to the previous year's 62.40 billion. Earnings were 12.88 billion, an increase of 55.61%.
Financial StatementsAnalyst Summary
According to 17 analysts, the average rating for ROP stock is "Buy." The 12-month stock price target is CHF 361.72, which is an increase of 1.86% from the latest price.
News
Roche announces EMA’s CHMP recommended approval of Susvimo
Roche (RHHBY) announced that the European Medicines Agency’s, EMA, Committee for Medicinal Products for Human Use, CHMP, has recommended the approval of Susvimo 100 mg/mL for the treatment of neovascu...
Roche receives FDA 510(k) clearance for cobas BV/CV assay
Roche (RHHBY) announced that it has received U.S. FDA 510(k) clearance for its cobas BV/CV assay. This molecular diagnostic test provides results for both Bacterial vaginosis and Candida vaginitis fro...
Roche receives FDA clearance for the cobas® BV/CV assay, enabling fast and highly accurate vaginitis diagnosis
The new PCR test uses clinician-collected or clinician-instructed, self-collected vaginal swab specimens to simultaneously detect organisms associated with Bacterial vaginosis (BV) and Candida vaginit...
CHMP recommends EU approval of Roche's Susvimo, the first continuous delivery treatment for neovascular age-related macular degeneration (nAMD)
Basel, 24 July 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Susv...
Roche Holding AG Earnings Call Transcript: H1 2026
Core operating profit rose 10% year-over-year, outpacing 6% sales growth, with margin expansion and strong contributions from both Pharma and Diagnostics. Multiple FDA priority reviews, robust pipeline progress, and disciplined capital allocation support a positive outlook for sustained growth.
Roche Holding AG Quarterly report: H1 2026
Roche Holding AG has published its H1 2026 quarterly earnings report on July 23, 2026.
Roche Holding AG Slides: H1 2026
Roche Holding AG has posted slides in relation to its H1 2026 quarterly earnings report, which was published on July 23, 2026.
Roche Holding AG Earnings release: H1 2026
Roche Holding AG released its H1 2026 earnings on July 23, 2026, summarizing the period's financial results.
Roche confirms FY26 outlook
Roche (RHHBY) expects an increase in Group sales in the mid single digit range for 2026. Core earnings per share are targeted to develop in the high single digit range.
Roche Backs Full-Year View as First-Half Sales Rise
The drugmaker's sales grew 6% on a constant exchange rate basis and exceeded analysts' expectations, according to a company compiled consensus.
Roche confirms full year targets as first-half sales fall
Swiss drugmaker Roche confirmed its full-year targets on Thursday as first-half sales fell in Swiss franc terms, dragged down by a strong domestic currency.
Roche showcases intelligent lab solutions and high-precision instruments at ADLM 2026 to help laboratories address workforce and workflow challenges
Supporting ADLM's focus on collaborative, cross-disciplinary solutions that address laboratory workforce and operational challenges Highlighting innovations in mass spectrometry, next-generation seque...
MaxCyte enters technology license partnership with Genentech
MaxCyte (MXCT) announced that it has entered into a technology license partnership with Genentech, a member of Roche (RHHBY), to support the development of cell therapy programs. The license provides…
Roche names Dan Malarek as President and CEO of Roche Diagnostics North America
Roche (RHHBY) announced the appointment of Dan Malarek as President and CEO of Roche Diagnostics North America, effective August 1. Malarek currently serves as Chief Executive Officer of Foundation Me...
Roche Appoints Dan Malarek as President and CEO of Roche Diagnostics North America
Dan Malarek, current CEO of Foundation Medicine Inc., appointed President and CEO of Roche Diagnostics North America, effective August 1, 2026 Malarek succeeds Brad Moore, who will retire at the end o...
Genentech granted priority review for Gazyva sBLA by FDA
Genentech, a member of Roche (RHHBY), announced that the FDA has granted priority review to the company’s supplemental biologics license application, or sBLA, for Gazyva for the treatment of primary…
FDA grants Priority Review to Roche's Gazyva/Gazyvaro for adults with primary membranous nephropathy
Basel, 15 July 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) has granted Priority Review to the company's supplemental Biologics License Appl...
FDA Grants Priority Review to Genentech's Gazyva for Adults With Primary Membranous Nephropathy
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $RHHBY--Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has grant...
Roche introduces cobas Hepatitis D Virus (HDV) test, the first fully automated diagnostic solution to identify the most severe form of viral hepatitis
Basel, 14 July 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that it introduces the cobas® HDV test for use on the cobas® 5800/6800/8800 systems, a diagnostic tool for the detection and qu...
Roche receives CE Mark for blood test to identify tuberculosis infection
Roche (RHHBY) announced that its Elecsys IGRA TB test has received the CE Mark, introducing a new blood testing solution for identifying tuberculosis infection in routine laboratory settings. “The new...
Roche receives CE Mark for blood test to identify tuberculosis infection
Basel, 9 July 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that its Elecsys IGRA TB test has received the CE Mark, introducing a new blood testing solution for identifying tuberculosis in...
The Market Just Got Shaken—These 3 ETFs May Come Out Stronger
Markets are being tested again. The AI trade has spent the past several weeks under real pressure, with memory, semiconductor, and neocloud names selling off hard after an extraordinary first half.
Roche presents new data in Alzheimer's disease from across its integrated pharmaceutical and diagnostics portfolio at AAIC
Basel, 7 July 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that it will present new data from its Alzheimer's disease portfolio at the Alzheimer's Association International Conference® 20...
Genentech and Roche Present New Data in Alzheimer's Disease From Across Its Integrated Pharmaceutical and Diagnostics Portfolio at AAIC
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $RHHBY--Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today that it will present new data from its Alzheimer's disease...
Roche downgraded to Hold from Buy at HSBC
HSBC downgraded Roche (RHHBY) to Hold from Buy with an unchanged price target of CHF 365. Vabysmo momentum might support the shares in the short-term as U.S. funding problems ease,…